Kali

KALY

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$101,824

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Share count rising — dilution

+38541.1% over 6y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 2.6M (2012) → 1.02B (2018)

Kali, Inc. is a small specialty pharmaceutical company that develops and sells prescription drugs. The company focuses on pain management medications, including abuse-deterrent formulations designed to reduce the risk of misuse. Its customers are primarily patients and healthcare providers in the United States.

Kali makes money by selling its prescription drug products to pharmacies, hospitals, and distributors. It operates almost entirely within the U.S. market and is a very small player in the broader generic and specialty drug industry. The company is currently unprofitable at the operating level, which is common for small drug makers still building out their product portfolio. The biggest risk it faces is competition from larger generic drug manufacturers with far greater resources, as well as the ongoing challenge of gaining wider prescriber adoption for its products.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+75.5% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+124.2% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

24.3%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$31M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Kali grew revenue 75% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

43.4%

Healthy — 43.4% gross margin

Operating Margin

28.5%

Excellent — 28.5% operating margin

ROCE

10.1%

Below par — 10.1% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+28.1%

Fast-growing sales (28.1% YoY)

EPS YoY

+72.9%

Earnings growing fast (72.9% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

17%

Weak — only 17% of profit becomes cash

FCF Margin

2.6%

Thin free cash flow (2.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

100.00x

—

Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

0.0x

Attractive valuation — P/E 0.0

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial